1. Cell Biology

C/EBPδ-induced epigenetic changes control the dynamic gene transcription of S100a8 and S100a9

  1. Saskia-Larissa Jauch-Speer
  2. Marisol Herrera-Rivero
  3. Nadine Ludwig
  4. Bruna Caroline Véras De Carvalho
  5. Leonie Martens
  6. Jonas Wolf
  7. Achmet Imam Chasan
  8. Anika Witten
  9. Birgit Markus
  10. Bernhard Schieffer
  11. Thomas Vogl
  12. Jan Rossaint
  13. Monika Stoll
  14. Johannes Roth  Is a corresponding author
  15. Olesja Fehler
  1. University of Münster, Germany
  2. University Hospital Münster, Germany
  3. University Hospital Marburg, Germany
https://doi.org/10.7554/eLife.75594
Share this article
Cite this article
  1. Saskia-Larissa Jauch-Speer
  2. Marisol Herrera-Rivero
  3. Nadine Ludwig
  4. Bruna Caroline Véras De Carvalho
  5. Leonie Martens
  6. Jonas Wolf
  7. Achmet Imam Chasan
  8. Anika Witten
  9. Birgit Markus
  10. Bernhard Schieffer
  11. Thomas Vogl
  12. Jan Rossaint
  13. Monika Stoll
  14. Johannes Roth
  15. Olesja Fehler
(2022)
C/EBPδ-induced epigenetic changes control the dynamic gene transcription of S100a8 and S100a9
eLife 11:e75594.
https://doi.org/10.7554/eLife.75594
  2. Download BibTeX
  3. Download .RIS

Abstract

The proinflammatory alarmins S100A8 and S100A9 are among the most abundant proteins in neutrophils and monocytes but are completely silenced after differentiation to macrophages. The molecular mechanisms of the extraordinarily dynamic transcriptional regulation of S100a8 and S100a9 genes, however, are only barely understood. Using an unbiased genome-wide CRISPR/Cas9 knockout based screening approach in immortalized murine monocytes we identified the transcription factor C/EBPδ as a central regulator of S100a8 and S100a9 expression. We showed that S100A8/A9 expression and thereby neutrophil recruitment and cytokine release were decreased in C/EBPδ KO mice in a mouse model of acute lung inflammation. S100a8 and S100a9 expression was further controlled by the C/EBPδ-antagonists ATF3 and FBXW7. We confirmed the clinical relevance of this regulatory network in subpopulations of human monocytes in a clinical cohort of cardiovascular patients. Moreover, we identified specific C/EBPδ-binding sites within S100a8 and S100a9 promoter regions, and demonstrated that C/EBPδ-dependent JMJD3-mediated demethylation of H3K27me3 is indispensable for their expression. Overall, our work uncovered C/EBPδ as a novel regulator of S100a8 and S100a9 expression. Therefore, C/EBPδ represents a promising target for modulation of inflammatory conditions that are characterised by S100a8 and S100a9 overexpression.

Data availability

data and code availabilityhttps://www.ncbi.nlm.nih.gov/bioproject/PRJNA754262https://www.ncbi.nlm.nih.gov/bioproject/PRJNA706411https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE200730

The following data sets were generated

Article and author information

Author details

  1. Saskia-Larissa Jauch-Speer

    Institute of Immunology, University of Münster, Münster, Germany
    Competing interests
    The authors declare that no competing interests exist.

  2. Marisol Herrera-Rivero

    Department of Genetic Epidemiology, University of Münster, Münster, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7064-9487

  3. Nadine Ludwig

    Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany
    Competing interests
    The authors declare that no competing interests exist.

  4. Bruna Caroline Véras De Carvalho

    Institute of Immunology, University of Münster, Münster, Germany
    Competing interests
    The authors declare that no competing interests exist.

  5. Leonie Martens

    Institute of Immunology, University of Münster, Münster, Germany
    Competing interests
    The authors declare that no competing interests exist.

  6. Jonas Wolf

    Institute of Immunology, University of Münster, Münster, Germany
    Competing interests
    The authors declare that no competing interests exist.

  7. Achmet Imam Chasan

    Institute of Immunology, University of Münster, Münster, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5137-6890

  8. Anika Witten

    Department of Genetic Epidemiology, University of Münster, Münster, Germany
    Competing interests
    The authors declare that no competing interests exist.

  9. Birgit Markus

    Clinic for Cardiology, Angiology and Internal Intensive Medicine, University Hospital Marburg, Marburg, Germany
    Competing interests
    The authors declare that no competing interests exist.

  10. Bernhard Schieffer

    Clinic for Cardiology, Angiology and Internal Intensive Medicine, University Hospital Marburg, Marburg, Germany
    Competing interests
    The authors declare that no competing interests exist.

  11. Thomas Vogl

    Institute of Immunology, University of Münster, Münster, Germany
    Competing interests
    The authors declare that no competing interests exist.

  12. Jan Rossaint

    Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany
    Competing interests
    The authors declare that no competing interests exist.

  13. Monika Stoll

    Department of Genetic Epidemiology, University of Münster, Münster, Germany
    Competing interests
    The authors declare that no competing interests exist.

  14. Johannes Roth

    Institute of Immunology, University of Münster, Münster, Germany
    For correspondence
    rothj@uni-muenster.de
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7035-8348

  15. Olesja Fehler

    Institute of Immunology, University of Münster, Münster, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6386-7080

Funding

Deutsche Forschungsgemeinschaft (CRC 1009 B9)

  • Johannes Roth

Deutsche Forschungsgemeinschaft (CRC 1009 Z2)

  • Johannes Roth

Deutsche Forschungsgemeinschaft (CRC 1009 B8)

  • Thomas Vogl

Deutsche Forschungsgemeinschaft (CRU 342 P3)

  • Johannes Roth

Deutsche Forschungsgemeinschaft (RO 1190/14-1)

  • Johannes Roth

Deutsche Forschungsgemeinschaft (CRU 342 P5)

  • Thomas Vogl

Interdisciplinary Center of Clinical Research at the University of Münster (Ro2/023/19)

  • Johannes Roth

Interdisciplinary Center of Clinical Research at the University of Münster (Vo2/011/19)

  • Thomas Vogl

EU EFRE Bio NRW programme (005-1007-0006)

  • Monika Stoll

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: Mouse experiments were in accordance with German Animal Welfare Legislation and performed as approved by the North Rhine-Westphalia Office of Nature, Environment and Consumer Protection (LANUV) and the District Government and District Veterinary Office Muenster under the reference number 81-02.04.2019.A445.

Human subjects: The BioNRW Study is conducted in accordance with the guidelines of the Declaration of Helsinki. The research protocol, including the case report forms, was approved by the local ethics committee (#245-12). Written informed consent was obtained from all study participants.

Copyright

© 2022, Jauch-Speer et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,536
    views
  • 283
    downloads
  • 17
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Saskia-Larissa Jauch-Speer
  2. Marisol Herrera-Rivero
  3. Nadine Ludwig
  4. Bruna Caroline Véras De Carvalho
  5. Leonie Martens
  6. Jonas Wolf
  7. Achmet Imam Chasan
  8. Anika Witten
  9. Birgit Markus
  10. Bernhard Schieffer
  11. Thomas Vogl
  12. Jan Rossaint
  13. Monika Stoll
  14. Johannes Roth
  15. Olesja Fehler
(2022)
C/EBPδ-induced epigenetic changes control the dynamic gene transcription of S100a8 and S100a9
eLife 11:e75594.
https://doi.org/10.7554/eLife.75594

Share this article

https://doi.org/10.7554/eLife.75594

Categories and tags

Research organism

Further reading

    1. Cancer Biology
    2. Cell Biology

    Changes in local mineral homeostasis facilitate the formation of benign and malignant testicular microcalcifications

    Ida Marie Boisen, Nadia Krarup Knudsen ... Martin Blomberg Jensen
    Research Article

    Testicular microcalcifications consist of hydroxyapatite and have been associated with an increased risk of testicular germ cell tumors (TGCTs) but are also found in benign cases such as loss-of-function variants in the phosphate transporter SLC34A2. Here, we show that fibroblast growth factor 23 (FGF23), a regulator of phosphate homeostasis, is expressed in testicular germ cell neoplasia in situ (GCNIS), embryonal carcinoma (EC), and human embryonic stem cells. FGF23 is not glycosylated in TGCTs and therefore cleaved into a C-terminal fragment which competitively antagonizes full-length FGF23. Here, Fgf23 knockout mice presented with marked calcifications in the epididymis, spermatogenic arrest, and focally germ cells expressing the osteoblast marker Osteocalcin (gene name: Bglap, protein name). Moreover, the frequent testicular microcalcifications in mice with no functional androgen receptor and lack of circulating gonadotropins are associated with lower Slc34a2 and higher Bglap/Slc34a1 (protein name: NPT2a) expression compared with wild-type mice. In accordance, human testicular specimens with microcalcifications also have lower SLC34A2 and a subpopulation of germ cells express phosphate transporter NPT2a, Osteocalcin, and RUNX2 highlighting aberrant local phosphate handling and expression of bone-specific proteins. Mineral disturbance in vitro using calcium or phosphate treatment induced deposition of calcium phosphate in a spermatogonial cell line and this effect was fully rescued by the mineralization inhibitor pyrophosphate. In conclusion, testicular microcalcifications arise secondary to local alterations in mineral homeostasis, which in combination with impaired Sertoli cell function and reduced levels of mineralization inhibitors due to high alkaline phosphatase activity in GCNIS and TGCTs facilitate osteogenic-like differentiation of testicular cells and deposition of hydroxyapatite.

    1. Cell Biology
    2. Genetics and Genomics

    Pyruvate and related energetic metabolites modulate resilience against high genetic risk for glaucoma

    Keva Li, Nicholas Tolman ... UK Biobank Eye and Vision Consortium
    Research Article

    A glaucoma polygenic risk score (PRS) can effectively identify disease risk, but some individuals with high PRS do not develop glaucoma. Factors contributing to this resilience remain unclear. Using 4,658 glaucoma cases and 113,040 controls in a cross-sectional study of the UK Biobank, we investigated whether plasma metabolites enhanced glaucoma prediction and if a metabolomic signature of resilience in high-genetic-risk individuals existed. Logistic regression models incorporating 168 NMR-based metabolites into PRS-based glaucoma assessments were developed, with multiple comparison corrections applied. While metabolites weakly predicted glaucoma (Area Under the Curve = 0.579), they offered marginal prediction improvement in PRS-only-based models (p=0.004). We identified a metabolomic signature associated with resilience in the top glaucoma PRS decile, with elevated glycolysis-related metabolites—lactate (p=8.8E-12), pyruvate (p=1.9E-10), and citrate (p=0.02)—linked to reduced glaucoma prevalence. These metabolites combined significantly modified the PRS-glaucoma relationship (Pinteraction = 0.011). Higher total resilience metabolite levels within the highest PRS quartile corresponded to lower glaucoma prevalence (Odds Ratiohighest vs. lowest total resilience metabolite quartile=0.71, 95% Confidence Interval = 0.64–0.80). As pyruvate is a foundational metabolite linking glycolysis to tricarboxylic acid cycle metabolism and ATP generation, we pursued experimental validation for this putative resilience biomarker in a human-relevant Mus musculus glaucoma model. Dietary pyruvate mitigated elevated intraocular pressure (p=0.002) and optic nerve damage (p<0.0003) in Lmx1bV265D mice. These findings highlight the protective role of pyruvate-related metabolism against glaucoma and suggest potential avenues for therapeutic intervention.

    1. Cell Biology

    Molecular mapping and functional validation of GLP-1R cholesterol binding sites in pancreatic beta cells

    Affiong Ika Oqua, Kin Chao ... Alejandra Tomas
    Research Article

    G protein-coupled receptors (GPCRs) are integral membrane proteins which closely interact with their plasma membrane lipid microenvironment. Cholesterol is a lipid enriched at the plasma membrane with pivotal roles in the control of membrane fluidity and maintenance of membrane microarchitecture, directly impacting on GPCR stability, dynamics, and function. Cholesterol extraction from pancreatic beta cells has previously been shown to disrupt the internalisation, clustering, and cAMP responses of the glucagon-like peptide-1 receptor (GLP-1R), a class B1 GPCR with key roles in the control of blood glucose levels via the potentiation of insulin secretion in beta cells and weight reduction via the modulation of brain appetite control centres. Here, we unveil the detrimental effect of a high cholesterol diet on GLP-1R-dependent glucoregulation in vivo, and the improvement in GLP-1R function that a reduction in cholesterol synthesis using simvastatin exerts in pancreatic islets. We next identify and map sites of cholesterol high occupancy and residence time on active vs inactive GLP-1Rs using coarse-grained molecular dynamics (cgMD) simulations, followed by a screen of key residues selected from these sites and detailed analyses of the effects of mutating one of these, Val229, to alanine on GLP-1R-cholesterol interactions, plasma membrane behaviours, clustering, trafficking and signalling in INS-1 832/3 rat pancreatic beta cells and primary mouse islets, unveiling an improved insulin secretion profile for the V229A mutant receptor. This study (1) highlights the role of cholesterol in regulating GLP-1R responses in vivo; (2) provides a detailed map of GLP-1R - cholesterol binding sites in model membranes; (3) validates their functional relevance in beta cells; and (4) highlights their potential as locations for the rational design of novel allosteric modulators with the capacity to fine-tune GLP-1R responses.